Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last?

Karyopharm Therapeutics (KPTI) shares rallied 27.9% in the last trading session to close at $7.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.3% loss over the past four weeks.The sudden gain in the stock price can be attributed to a positive investor mindset regarding the continued strong uptake of Karyopharm Therapeutics’ only marketed product, Xpovio (selinexor), approved for multiple myeloma and B-cell lymphoma indications. The company is also currently evaluating the drug as a monotherapy or in combination across several other cancer indications in separate late-stage studies.This pharmaceutical company is expected to post quarterly loss of $3.67 per share in its upcoming report, which represents a year-over-year change of +5.9%. Revenues are expected to be $40.2 million, up 3.7% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Karyopharm Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KPTI going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Karyopharm Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Akebia Therapeutics (AKBA), finished the last trading session 1.4% higher at $2.83. AKBA has returned -7.9% over the past month.For Akebia Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. This represents a change of +80% from what the company reported a year ago. Akebia Therapeutics currently has a Zacks Rank of #3 (Hold).Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Karyopharm Therapeutics Inc. (KPTI): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks